Register Login

BIOCRYST PHARMACEUTICALS INC (BCRX)

SymbolBCRX
NameBIOCRYST PHARMACEUTICALS INC
SectorHEALTH CARE
RegionUNDEFINED
IndustryBiological Products, (No Diagnostic Substances)
Address4505 EMPEROR BOULEVARD, DURHAM, NC 27703
Telephone919-859-1302
Fax—
Email—
Websitehttps://www.biocryst.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK—
Description

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocrysts research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

Additional info from NASDAQ:
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocrysts research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

2026-04-28 11:00

BioCryst to Present at Upcoming Investor Conferences

Read more
2026-04-23 17:12

New Form DEFA14A - BIOCRYST PHARMACEUTICALS INC <b>Filed:</b> 2026-04-23 <b>AccNo:</b> 0001140361-26-016373 <b>Size:</b> 263 KB

Read more
2026-04-23 17:02

New Form DEF 14A - BIOCRYST PHARMACEUTICALS INC <b>Filed:</b> 2026-04-23 <b>AccNo:</b> 0001628280-26-026822 <b>Size:</b> 3 MB

Read more
2026-04-15 11:00

BioCryst to Report First Quarter 2026 Financial Results on May 6

Read more
2026-04-07 20:24

Menon Sandeep 🟢 acquired 646.5K shares (1 derivative) of BIOCRYST PHARMACEUTICALS INC (BCRX) at $9.47 ($4.2M) Transaction Date: Apr 06, 2026 | Filing ID: 000019

Read more
2026-04-07 17:23

New Form 3 - BIOCRYST PHARMACEUTICALS INC <b>Filed:</b> 2026-04-07 <b>AccNo:</b> 0001171843-26-002301 <b>Size:</b> 11 KB

Read more
2026-04-06 11:00

BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer

Read more
2026-04-03 11:00

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more
2026-03-26 17:09

New Form SCHEDULE 13G/A - BIOCRYST PHARMACEUTICALS INC <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-000742 <b>Size:</b> 7 KB

Read more
2026-03-24 20:02

Director HEGGIE THERESA 🟡 adjusted position in 49.9K shares (1 derivative) of BIOCRYST PHARMACEUTICALS INC (BCRX) at $10.11 ($1.1M) Transaction Date: Mar 20, 2026 | Filing ID: 000017

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT04428632 Oral Berotralstat Expanded Access Program — Hereditary Angioedema Approved_For_Marketing — — ClinicalTrials.gov
NCT07228559 A Study of Avoralstat In Participants With Diabetic Macular Edema Phase1 Diabetic Macular Edema (DME) Active_Not_Recruiting 2025-10-02 2026-09-01 ClinicalTrials.gov
NCT05453968 Berotralstat Treatment in Children With Hereditary Angioedema Phase3 Hereditary Angioedema Active_Not_Recruiting 2022-10-25 2027-02-01 ClinicalTrials.gov
NCT05116774 BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Parti… Phase2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Terminated 2021-12-06 2023-09-14 ClinicalTrials.gov
NCT04702568 A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal H… Phase2 Paroxysmal Nocturnal Hemoglobinuria Terminated 2020-12-18 2023-10-04 ClinicalTrials.gov
NCT03485911 Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of… Phase3 Hereditary Angioedema Completed 2018-02-06 2022-04-06 ClinicalTrials.gov
NCT03136237 A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions Phase1 Hereditary Angioedema Completed 2017-02-17 2017-08-15 ClinicalTrials.gov
NCT02448264 First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and… Phase1 Hereditary Angioedema Completed 2015-05-01 2015-12-01 ClinicalTrials.gov
NCT02367313 A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinov… Phase2 Asthma Completed 2015-02-01 2016-12-01 ClinicalTrials.gov
NCT02101866 A Study to Compare the Oral Bioavailability of Single Doses of Two Vapendavir D… Phase1 Healthy Completed 2014-03-01 2014-06-01 ClinicalTrials.gov
NCT01984788 Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE Phase2 Hereditary Angioedema Completed 2013-11-01 2014-05-01 ClinicalTrials.gov
NCT01146353 Pharmacokinetic Assessment of Peramivir in Hospitalized Adults Undergoing Conti… — Influenza Withdrawn 2010-02-01 2011-02-01 ClinicalTrials.gov
NCT00985127 Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Admini… Phase2 Gout Completed 2009-09-01 2010-09-01 ClinicalTrials.gov
NCT00289562 Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia Phase1 B-cell Acute Lymphoblastic Leukemia Completed 2004-09-01 2007-12-01 ClinicalTrials.gov
Total clinical trials: 14
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
BTA-C585 matching placebo DRUG Phase PHASE1 Pharmacokinetics COMPLETED NCT02668367
BTA-C585 oral capsules DRUG Phase PHASE1 Pharmacokinetics COMPLETED NCT02668367
Vapendavir 132 mg capsules DRUG Phase PHASE1 Healthy COMPLETED NCT02101866
Vapendavir 300 mg tablet DRUG Phase PHASE1 Healthy COMPLETED NCT02101866
Vapendavir DRUG Phase PHASE2 Asthma COMPLETED NCT02367313
BCX17725 DRUG Phase PHASE1 Netherton Syndrome RECRUITING NCT06539507
BCX10013 DRUG Phase PHASE1 Paroxysmal Nocturnal Hemoglobinuria COMPLETED NCT06100900
BCX9930 monotherapy DRUG Phase PHASE2 Paroxysmal Nocturnal Hemoglobinuria (PNH) TERMINATED NCT05116787
berotralstat DRUG Phase PHASE3 Hereditary Angioedema ENROLLING_BY_INVITATION NCT04933721
Ravulizumab DRUG Phase PHASE2 Paroxysmal Nocturnal Hemoglobinuria (PNH) TERMINATED NCT05116774
Eculizumab DRUG Phase PHASE2 Paroxysmal Nocturnal Hemoglobinuria (PNH) TERMINATED NCT05116774
Berotralstat DRUG Phase PHASE3 Hereditary Angioedema ACTIVE_NOT_RECRUITING NCT05453968
BCX9930 DRUG Phase PHASE2 Paroxysmal Nocturnal Hemoglobinuria TERMINATED NCT05741346
Galidesivir DRUG Phase PHASE1 COVID-19 TERMINATED NCT03891420
galidesivir DRUG Phase PHASE1 Marburg Virus Disease COMPLETED NCT03800173
Placebo oral capsule DRUG Phase PHASE3 Hereditary Angioedema, HAE COMPLETED NCT03873116
BCX7353 capsules DRUG Phase PHASE3 Hereditary Angioedema, HAE COMPLETED NCT03873116
Cyclosporine + BCX7353 DRUG Phase PHASE1 Hereditary Angioedema COMPLETED NCT03136237
rosuvastatin + BCX7353 DRUG Phase PHASE1 Hereditary Angioedema COMPLETED NCT03136237
Rosuvastatin DRUG Phase PHASE1 Hereditary Angioedema COMPLETED NCT03136237
BCX7353 + digoxin DRUG Phase PHASE1 Hereditary Angioedema COMPLETED NCT03136237
Digoxin DRUG Phase PHASE1 Hereditary Angioedema COMPLETED NCT03136237
BCX7353 and probes DRUG Phase PHASE1 Hereditary Angioedema COMPLETED NCT02819102
avoralstat DRUG Phase PHASE1 Diabetic Macular Edema (DME) ACTIVE_NOT_RECRUITING NCT07228559
Placebo to match BCX7353 DRUG Phase PHASE1 Hereditary Angioedema COMPLETED NCT02448264
BCX7353 DRUG Phase PHASE2 Hereditary Angioedema COMPLETED NCT03472040
BCX4430 DRUG Phase PHASE1 Filovirus Infections COMPLETED NCT02319772
BCX4161 DRUG Phase PHASE2 Hereditary Angioedema COMPLETED NCT02303626
Ulodesine (BCX4208) 10 mg DRUG Phase PHASE2 Gout COMPLETED NCT01407874
Ulodesine (BCX4208) 5 mg DRUG Phase PHASE2 Gout COMPLETED NCT01407874
ulodesine DRUG Phase PHASE2 Gout COMPLETED NCT01265264
Placebo Comparator DRUG Phase PHASE3 Influenza TERMINATED NCT01224795
Allopurinol DRUG Phase PHASE2 Gout COMPLETED NCT01129648
BCX4208 DRUG Phase PHASE2 Gout COMPLETED NCT01129648
placebo DRUG Phase PHASE1 Marburg Virus Disease COMPLETED NCT03800173
Placebo+SOC DRUG Phase PHASE3 Cough TERMINATED NCT00958776
Peramivir+SOC DRUG Phase PHASE3 Cough TERMINATED NCT00958776
forodesine HCl DRUG Phase PHASE2 Chronic Lymphocytic Leukemia (CLL) COMPLETED NCT00640523
Oseltamivir DRUG Phase PHASE3 Influenza COMPLETED NCT02369159
Peramivir 400 mg DRUG Phase PHASE2 Influenza COMPLETED NCT00453999
Peramivir 200 mg DRUG Phase PHASE2 Influenza COMPLETED NCT00453999
forodesine hydrochloride (BCX-1777) DRUG Phase PHASE1 B-cell Acute Lymphoblastic Leukemia COMPLETED NCT00289562
Peramivir DRUG Phase PHASE2 Influenza COMPLETED NCT02665351
Forodesine 200 mg DRUG Phase PHASE2 Cutaneous T-cell Lymphoma (CTCL), COMPLETED NCT00501735
Peramivir 300mg DRUG Phase PHASE3 Influenza WITHDRAWN NCT00486980
Peramivir 150mg DRUG Phase PHASE3 Influenza WITHDRAWN NCT00486980
Placebo DRUG Phase PHASE2 Asthma COMPLETED NCT02367313
Peramivir 300 mg DRUG Phase PHASE2 Influenza COMPLETED NCT00419263
Peramivir 150 mg DRUG Phase PHASE2 Influenza COMPLETED NCT00419263
Forodesine Hydrochloride Capsules (100 mg) DRUG Phase PHASE2 Leukemia TERMINATED NCT00419081
Forodesine Hydrochloride Sterile Solution, 5 mg/mL DRUG Phase PHASE2 Leukemia TERMINATED NCT00419081
forodesine hydrochloride DRUG Phase PHASE1 Lymphoma COMPLETED NCT00098332
BCX-1777 DRUG Phase PHASE1 Leukemia, Lymphocytic COMPLETED NCT00035022
Peldesine DRUG Phase PHASE1 HIV Infections COMPLETED NCT00002237
Total products: 54